ADRs of German chemical and pharmaceutical maker Merck KGaA (MKGAY.PK +0.7%) get a lift after receiving a positive opinion from a committee of the European Medicines Agency for its application to extend the indication of Rebif, its leading treatment for relapsing forms of multiple sclerosis.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs